Skip to content

Study · Randomized controlled trial · n = 102 · 2021

4 results

Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial.

Rasmussen IKB, Zobel EH, Ripa RS, von Scholten BJ, Curovic VR, Jensen JK, Kjaer A, Hansen TW, Rossing P

Diabetes, obesity & metabolism26 Aug 2021Cited by 10 (Europe PMC)

PMID34387408 (opens in a new tab)DOI10.1111/dom.14516 (opens in a new tab)PepBankPUB-34387408
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 26 weeks of liraglutide reduced cardiac adipose tissue volume significantly more than placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide reduced fat around the heart more than placebo over 26 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseCardiac adipose tissue volume, between-group difference
    Study

    n = 102

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Measurements

    Mean difference in cardiac adipose tissue
    −11.4 mL
    liraglutide versus placebo

    Source sentences

    Summary
    The reduction in cardiac adipose tissue was significantly greater in the liraglutide compared to the placebo group (mean difference -11.4 [-19.4, -3.3] mL; P = 0.006)
    1 context sentence
    Summary · context
    Participants with type 2 diabetes were randomized to treatment with liraglutide 1.8 mg/d or placebo for 26 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the difference in cardiac adipose tissue between liraglutide and placebo was no longer significant after adjustment for changes in BMI.

    In plain wordsIn adults with type 2 diabetes, after accounting for BMI change, liraglutide no longer reduced fat around the heart significantly more than placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeCardiac adipose tissue difference after adjustment for BMI change
    Study

    n = 102

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    but significance was lost after adjustment for changes in body mass index (P = 0.46).
    1 context sentence
    Summary · context
    Participants with type 2 diabetes were randomized to treatment with liraglutide 1.8 mg/d or placebo for 26 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, cardiac adipose tissue volume fell from baseline with liraglutide for 26 weeks, but not with placebo.

    In plain wordsIn adults with type 2 diabetes, fat around the heart fell with liraglutide over 26 weeks but not with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseCardiac adipose tissue change from baseline in the liraglutide group
    Study

    n = 51

    Analysis
    Secondary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Measurements

    Cardiac adipose tissue change
    −11.5 mL
    liraglutide
    Cardiac adipose tissue change
    −0.01 mL
    placebo

    Source sentences

    Summary
    From baseline to end of treatment the mean cardiac adipose tissue change was -11.5 (95% confidence interval -17.6, -5.4) mL in the liraglutide (P < 0.001) and -0.01 (-5.3, 5.3) mL in the placebo (P = 1.00) groups.
    1 context sentence
    Summary · context
    Participants with type 2 diabetes were randomized to treatment with liraglutide 1.8 mg/d or placebo for 26 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, mean body weight change was -3.7 kg with liraglutide and -0.18 kg with placebo over 26 weeks.

    In plain wordsIn adults with type 2 diabetes, people on liraglutide lost about 3.7 kg over 26 weeks, compared with about 0.18 kg on placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 102

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Measurements

    Body weight change
    −3.7 kg
    liraglutide
    Body weight change
    −0.18 kg
    placebo

    Source sentences

    Summary
    The mean change in body weight was -3.7 (-4.8, -2.6) kg in the liraglutide and -0.18 (-0.76, 0.40) kg in the placebo group.
    1 context sentence
    Summary · context
    Participants with type 2 diabetes were randomized to treatment with liraglutide 1.8 mg/d or placebo for 26 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.